sinc
last
handbook
clinic
neurolog
volum
topic
viral
diagnosi
made
tremend
stride
move
margin
mainstream
clinic
care
chang
driven
mani
factor
importantli
effect
antivir
therapi
mani
year
convent
viru
isol
mainstay
viral
diagnosi
sinc
sensit
openmind
howev
cell
cultur
special
techniqu
requir
highli
skill
personnel
addit
growth
convent
cell
cultur
entail
inher
delay
limit
clinic
impact
although
rapid
cultur
viral
antigen
method
detect
fewer
pathogen
less
sensit
convent
cultur
requir
less
expertis
greatli
reduc
time
result
previou
edit
text
nucleic
acid
hybrid
highlight
howev
esoter
expens
method
yet
sensit
thu
limit
clinic
applic
polymeras
chain
reaction
pcr
usher
new
era
virolog
especi
diagnosi
neurolog
diseas
molecular
amplif
method
includ
limit
pcr
rapid
highli
sensit
detect
virus
amen
routin
cultur
autom
quantit
varieti
avail
test
method
commerci
product
prolifer
challeng
clinician
laboratori
select
test
util
clinic
scenario
understand
interpret
result
test
modal
advantag
limit
tabl
discuss
chapter
special
attent
neurolog
diseas
detail
descript
test
method
reader
refer
textbook
viral
diagnosi
specter
et
al
jerom
tang
crow
viral
diagnost
test
undertaken
either
document
prior
infect
assist
diagnosi
acut
ill
chapter
focu
diseas
diagnosi
ideal
viral
infect
fig
viral
replic
clinic
symptom
appear
immunoglobulin
igm
igg
antibodi
elimin
viru
resolut
diseas
occur
predict
progress
diseas
consequ
viral
replic
host
cell
lysi
diagnost
effort
focus
detect
viru
sampl
collect
earli
possibl
ill
viru
titer
maxim
altern
diseas
process
mediat
host
respons
viral
infect
detect
antibodi
key
virus
associ
immunemedi
diseas
includ
epsteinbarr
viru
ebv
hepat
b
viru
hbv
parvoviru
unfortun
import
deviat
scenario
acut
infect
progress
viral
clearanc
viral
persist
latenc
reactiv
late
diseas
thu
pattern
particular
viru
well
immun
compet
host
consid
order
test
interpret
result
virus
requir
live
cell
order
replic
earli
work
virolog
util
primat
embryon
egg
less
sensit
method
limit
test
menu
naat
gener
comment
sensit
method
detect
virus
grow
cultur
rapid
cultur
safer
cultur
sinc
pathogen
inactiv
disrupt
test
potenti
autom
quantif
requir
special
equip
expertis
result
variabl
across
laboratori
inhibitor
prevent
amplif
crosscontamin
lead
fals
posit
detect
clinic
irrelev
virus
genet
variabl
lead
falseneg
result
fdaapprov
assay
convent
pcr
hour
use
inexpens
convent
thermocycl
less
affect
genom
variabl
amen
multiplex
test
realtim
assay
prone
carryov
contamin
amplifi
product
sinc
tube
open
amplif
slower
realtim
method
ethidium
bomid
use
amplicon
detect
toxic
realtim
pcr
hour
faster
less
prone
crosscontamin
readili
quantifi
labdevelop
assay
readili
updat
commerci
kit
becom
avail
includ
walkaway
test
suckl
mice
suscept
anim
host
recognit
virus
could
propag
cultur
human
anim
cell
led
nobel
prize
ender
weller
robbin
isol
cell
cultur
becam
gold
standard
viral
diagnosi
mortim
varieti
differ
cell
line
need
cultur
broad
spectrum
clinic
signific
virus
landri
clinic
laboratori
three
basic
categori
cell
line
use
primari
diploid
continu
heteroploid
tabl
laboratori
perform
convent
viral
cultur
inocul
clinic
specimen
two
three
differ
cell
line
depend
virus
sought
leland
ginocchio
cultur
incub
monitor
week
appear
characterist
viral
cytopath
effect
cpe
fig
time
detect
cpe
convent
cultur
determin
viru
inoculum
growth
pattern
specif
viru
cell
line
inocul
whether
cultur
rotat
temperatur
incub
frequenc
examin
cpe
seen
viru
isol
identifi
commonli
immunofluoresc
stain
cultur
cell
absenc
cpe
hemadsorpt
appli
weak
solut
guinea
red
cell
cell
monolay
use
screen
presenc
hemagglutinin
protein
express
surfac
cell
infect
influenza
parainfluenza
virus
acid
labil
test
use
differenti
rhinovirus
acidlabil
enterovirus
acidst
advantag
convent
viral
cultur
includ
abil
detect
mani
virus
obtain
viral
isol
unfortun
identif
virus
convent
cultur
take
sever
week
due
slow
growth
virus
low
viral
inocula
accur
interpret
cpe
requir
technic
skill
experienc
laboratori
staff
may
avail
volum
sampl
test
limit
exampl
cerebrospin
fluid
csf
fewer
cell
type
inocul
yield
convent
cultur
reduc
landri
et
al
addit
csf
contamin
blood
may
toxic
cultur
cell
virus
grown
use
common
cell
line
cultur
virus
restrict
higher
biosafetylevel
facil
inde
laboratori
notifi
promptli
possibl
recov
biosafeti
level
virus
arboviru
zoonot
virus
http
wwwcdcgovbiosafetypubl
altern
test
select
limit
number
specif
virus
consid
differenti
diagnosi
target
approach
use
rapid
cultur
use
shell
vial
shell
vial
name
resembl
shotgun
shell
small
vial
base
contain
coverslip
coat
cell
monolay
sampl
inocul
vial
centrifug
increas
sensit
lead
synonym
rapid
centrifug
cultur
predetermin
time
point
inocul
coverslip
remov
shell
vial
cell
monolay
fix
aceton
subject
stain
monoclon
antibodi
mab
specif
virus
fig
shell
vial
cultur
commonli
examin
day
incub
onset
cpe
gleav
et
al
case
shell
vial
may
incub
longer
assess
cpe
current
mani
rapid
cultur
system
use
mix
cell
instead
singl
cell
line
mix
cell
support
growth
sever
virus
caus
similar
clinic
syndrom
involv
inocul
one
cell
mixtur
rather
multipl
vial
contain
differ
cell
line
exampl
rmix
cell
incorpor
mink
lung
cell
singl
vial
huang
turchek
day
postinocul
cultur
stain
pool
mab
respiratori
syncyti
viru
rsv
influenza
type
b
parainfluenza
type
adenoviru
recent
hmpv
cpe
appar
fong
et
al
weinberg
et
al
neither
cell
line
alon
would
allow
recoveri
virus
mix
cell
also
avail
isol
enterovirus
super
emix
varicellazost
viru
vzv
h
v
mix
huang
et
al
b
genet
modifi
cell
line
develop
transfect
viral
receptor
cell
line
enhanc
cell
suscept
viru
infect
eg
super
emix
cell
introduc
genet
element
upon
viral
infect
trigger
product
measur
enzym
visibl
stain
infect
cell
enzymelink
induc
system
elvi
crist
et
al
rapid
cultur
method
detect
wide
varieti
virus
convent
cultur
howev
compar
convent
cultur
rapid
cultur
provid
result
clinic
relev
timefram
implement
less
skill
personnel
barenfang
et
al
thu
due
combin
rel
speed
sensit
compar
antigen
test
eas
use
rapid
cultur
method
continu
find
nich
mani
viral
diagnost
laboratori
presenc
antibodi
indic
past
exposur
viru
receipt
vaccin
crossreact
highli
relat
viru
even
passiv
transfer
antibodi
blood
product
immunoglobulin
administ
igm
antibodi
produc
earli
infect
transient
thu
presenc
antiviru
igm
consid
synonym
current
recent
uninfect
convent
cell
cultur
upper
panel
cell
demonstr
cmv
cytopath
effect
day
inocul
lower
panel
b
rapid
shell
vial
cultur
cell
hour
inocul
fixat
aceton
cell
monolay
stain
monoclon
antibodi
cmv
immedi
earli
antigen
magnif
strong
nuclear
stain
indic
cmv
infect
inset
magnif
infect
jame
seroconvers
neg
posit
igg
appropri
timefram
strongest
evid
recent
viral
infect
proper
clinic
context
fourfold
rise
serum
antibodi
titer
also
consid
diagnost
howev
clinic
laboratori
still
perform
antibodi
titer
ie
serial
dilut
serum
sampl
test
dilut
determin
endpoint
titer
lowavid
igg
antibodi
suggest
recent
infect
thu
avid
test
use
pregnanc
estim
whether
cytomegaloviru
cmv
rubella
igg
reflect
recent
primari
infect
hofmann
liebert
lazzarotto
et
al
csf
test
intrathec
product
antivir
antibodi
marker
central
nervou
system
cn
infect
arbovirus
detect
igm
antibodi
csf
prefer
molecular
test
viral
nucleic
acid
although
use
test
necessari
maximum
sensit
princ
et
al
detect
virusspecif
igg
csf
requir
sampl
collect
later
cours
infect
igm
exclus
passiv
transfer
igg
blood
csf
igg
molecul
easili
diffus
across
bloodbrain
barrier
presenc
csf
may
simpli
reflect
high
serum
antibodi
level
thu
pair
csf
serum
sampl
must
test
antibodi
suspect
pathogen
well
control
viru
pathogen
andiman
commonli
use
diagnosi
hsv
enceph
past
aureliu
et
al
csf
antivir
igg
test
replac
igm
test
pcr
neutral
test
measur
abil
patient
antibodi
neutral
infect
protect
cell
infect
consid
gold
standard
assess
protect
antibodi
use
routin
diagnosi
confin
specialti
public
health
laboratori
special
indic
differenti
among
highli
relat
arbovirus
serotyp
enterovirus
kuno
malan
et
al
method
challeng
dose
infecti
viru
mix
serial
dilut
patient
serum
incub
mixtur
inocul
cell
cultur
monolay
often
monolay
overlay
semisolid
medium
facilit
product
virusinfect
foci
plaqu
defin
incub
period
monolay
fix
stain
virusinduc
plaqu
count
endpoint
dilut
patient
serum
reduc
plaqu
format
thu
assay
also
call
plaqu
reduct
neutral
test
prnt
mani
year
complement
fixat
wide
use
clinic
virolog
inexpens
manual
requir
care
inhous
standard
qualiti
control
less
sensit
current
method
current
confin
public
health
laboratori
method
avail
hemagglutin
inhibit
wide
use
virus
surfac
protein
agglutin
red
blood
cell
still
use
public
health
research
laboratori
assess
antibodi
respons
specif
strain
influenza
virus
especi
vaccin
assay
use
detect
igm
igg
commerci
kit
avail
ebv
arbovirus
malan
et
al
virusinfect
cultur
cell
mix
uninfect
cell
affix
glass
microscop
slide
dilut
patient
serum
ad
incub
period
wash
step
bound
antibodi
detect
addit
antihuman
antibodi
conjug
fluorescein
excel
test
done
well
requir
fluoresc
microscop
extens
train
judgment
interpret
result
laborintens
subject
suit
highvolum
test
solidphas
immunoassay
spia
larg
replac
method
serolog
test
routin
clinic
laboratori
frequent
perform
autom
highthroughput
instrument
term
solidphas
immunoassay
refer
immobil
antigen
antibodi
solid
phase
microtit
plate
microparticl
assay
take
sever
form
fig
common
type
spia
noncompetit
indirect
enzym
immunoassay
eia
fig
indirect
eia
patient
serum
allow
react
immobil
viral
antigen
presenc
bound
virusspecif
antibodi
detect
use
mab
coupl
enzym
eg
alkalin
phosphatas
horseradish
peroxidas
presenc
appropri
substrat
produc
colorimetr
fluoresc
signal
whose
intens
directli
relat
amount
antibodi
present
origin
sampl
enzymecoupl
antibodi
could
specif
isotyp
nearli
noncompetit
eia
use
iggspecif
antibodi
detect
commonli
use
assay
detect
antiviru
igm
differ
format
see
competit
spia
viral
antigen
immobil
known
amount
enzymecoupl
virusspecif
antibodi
includ
reaction
mixtur
fig
virusspecif
antibodi
present
patient
serum
compet
enzymecoupl
antibodi
result
signal
indirectli
relat
amount
antibodi
present
patient
specimen
type
assay
abl
detect
igm
igg
assay
commonli
use
hbv
core
total
dr
peaper
ml
landri
antibodi
hepat
viru
hav
total
antibodi
assay
anoth
format
allow
detect
igm
well
igg
doubleantigen
sandwich
fig
immobil
viral
antigen
bind
antivir
antibodi
patient
sampl
bound
antibodi
detect
enzymecoupl
viral
antigen
rather
antiigg
conjug
follow
addit
substrat
number
advanc
immunoassay
past
year
evid
evolut
human
immunodefici
viru
hiv
serolog
test
first
gener
hiv
assay
perform
manual
use
micropl
bead
tube
target
antigen
deriv
wholeviru
lysat
increas
specif
secondgener
assay
use
recombin
protein
synthet
peptid
antigen
sourc
includ
thirdgener
hiv
assay
includ
antigen
detect
group
variant
employ
doubleantigen
sandwich
design
detect
igm
well
igg
reduc
antibodyneg
window
period
week
burgiss
et
al
final
fourthgener
hiv
assay
avail
europ
first
becam
avail
unit
state
detect
hiv
antigen
well
antibodi
miedoug
et
al
antigenantibodi
combin
assay
allow
earli
detect
infect
antibodi
emerg
shorten
window
period
approxim
week
sicking
et
al
branson
anoth
major
advanc
use
randomaccess
instrument
commonli
use
chemistri
laboratori
infecti
diseas
serolog
tradit
microplatebas
serolog
assay
sampl
batchtest
plate
progress
unit
reagent
addit
incub
wash
detect
step
order
reduc
cost
increas
effici
one
batch
must
complet
requir
hour
next
batch
load
instrument
sampl
may
held
queue
sever
day
suffici
larg
number
specimen
avail
test
contrast
randomaccess
platform
allow
sampl
test
varieti
analyt
load
test
continu
dramat
reduc
turnaround
time
random
access
ondemand
method
often
use
chemiluminesc
label
produc
light
excit
chemic
energi
chemiluminesc
immunoassay
clia
sensit
less
prone
interfer
lower
background
signal
eia
kim
et
al
randomaccess
instrument
also
develop
molecular
test
see
eia
still
perform
manual
analyt
kit
use
autom
instrument
yet
avail
falseposit
falseneg
result
major
concern
test
virusspecif
igm
high
level
igg
block
bind
igm
viral
antigen
solid
phase
lead
falseneg
result
sera
contain
rheumatoid
factor
igm
antibodi
antiigg
specif
prone
falseposit
result
method
remov
interf
igg
rheumatoid
factor
sera
prior
test
develop
martin
et
al
altern
pretreat
serum
igm
class
captur
assay
also
call
revers
captur
captur
fig
method
antiigm
immobil
solid
phase
bind
igm
antibodi
patient
serum
regardless
specif
viral
antigen
incub
bound
igm
enzymecoupl
virusspecif
antibodi
use
detect
bound
viral
antigen
igm
captur
assay
consid
sensit
specif
format
besselaar
et
al
howev
west
nile
viru
particular
addit
background
subtract
step
need
reduc
nonspecif
reactiv
avoid
falseposit
result
rawlin
et
al
latex
agglutin
assay
among
simplest
perform
wide
use
diagnosi
acut
infecti
mononucleosi
latex
agglutin
latex
particl
coat
target
antigen
incub
presenc
patient
serum
contain
specif
antibodi
latex
particl
form
clump
becom
visibl
nake
eye
latex
agglutin
test
use
paulbunnel
antigen
larg
supplant
origin
monospot
test
heterophil
antibodi
use
bovin
hors
red
blood
cell
follow
adsorpt
guinea
pig
kidney
bruu
et
al
latex
agglutin
test
subject
prozon
effect
wherein
high
level
antibodi
gener
fals
neg
result
due
satur
antibodybind
site
minim
agglutin
later
flow
immunochromatographi
ic
assay
develop
serolog
test
food
drug
administr
fda
approv
pointofcar
test
patient
specimen
mix
test
buffer
mixtur
either
appli
sampl
load
pad
test
devic
insert
sampl
buffer
mixtur
depend
kit
antibodi
present
sampl
react
label
antigen
strip
antigenantibodydetector
conjug
complex
drawn
along
test
strip
capillari
action
captur
specif
antibodi
test
area
give
rise
visibl
line
spot
rapid
hiv
antibodi
test
ic
test
detect
antihiv
antibodi
serum
saliva
oral
mucos
transud
delaney
et
al
recent
similar
test
develop
hepat
c
viru
hcv
lee
et
al
western
blot
viral
protein
infect
cell
lysat
load
gel
subject
electrophoresi
separ
molecular
weight
transfer
nitrocellulos
membran
immobil
recombin
immunoblot
assay
riba
also
call
strip
immunoblot
recombin
synthet
peptid
directli
appli
membran
patient
serum
incub
membran
follow
incub
antiigg
coupl
enzym
addit
substrat
lead
deposit
color
substrat
site
antibodi
bind
specif
antibodyantigen
reactiv
visual
criteria
establish
interpret
immunoblot
report
often
includ
ident
intens
reactiv
band
western
blot
commonli
use
confirm
screen
assay
human
tlymphotroph
viru
htlv
iii
differenti
infect
wald
ashleymorrow
mahajan
et
al
riba
use
confirm
hcv
screen
test
manufactur
ceas
product
damen
et
al
virus
small
seen
convent
light
microscopi
electron
microscopi
em
techniqu
allow
direct
visual
virus
biel
gelderblom
recognit
viral
morpholog
ultrastructur
detail
virusinfect
cell
basi
viral
identif
em
requir
substanti
expertis
two
em
method
use
viral
identif
neg
stain
thin
section
contrast
virus
background
em
imag
depend
differ
electron
densiti
structur
examin
neg
stain
electrondens
finegrain
heavymet
salt
ad
sampl
stain
materi
accumul
around
viru
within
featur
viral
capsid
envelop
area
lack
stain
appear
white
black
background
viral
structur
accumul
stain
may
appear
differ
shade
gray
approxim
virionsml
need
visual
neg
stain
specimen
may
requir
highspe
centrifug
concentr
virus
vesicular
fluid
stool
csf
tissu
cultur
supernat
urin
serum
amen
em
analysi
immun
em
addit
specif
antibodi
lead
aggreg
viral
particl
facilit
visual
led
discoveri
mani
gastroenter
virus
stool
extract
thin
section
perform
tissu
biopsi
cell
histopatholog
find
suggest
viral
infect
fixat
embed
polym
resin
sampl
section
analog
paraffinembed
tissu
patholog
prepar
section
much
thinner
stain
perform
use
heavymet
salt
em
viral
diagnosi
offer
laboratori
howev
em
prove
invalu
identif
novel
uncultur
virus
includ
recent
describ
sever
acut
respiratori
syndrom
sar
coronaviru
drosten
et
al
ksiazek
et
al
viru
particl
seen
light
microscopi
viral
infect
detect
tissu
specimen
use
morpholog
featur
special
stain
techniqu
viral
replic
distort
normal
cellular
nuclear
architectur
give
rise
appear
groundglass
nuclei
multinucl
cell
form
cytoplasm
andor
nuclear
inclus
characterist
particular
viral
infect
specif
test
may
perform
immunohistochemistri
situ
hybrid
ish
identifi
virus
tissu
histopatholog
diagnosi
viral
infect
describ
detail
chapter
detect
viral
antigen
clinic
sampl
provid
direct
evid
viral
infect
contrast
cultur
pcr
antigen
detect
method
amplifi
target
viru
make
inher
less
sensit
anoth
limit
antigen
variabl
target
virus
vari
year
year
especi
influenza
thu
perform
particular
kit
may
vari
year
year
novel
variant
emerg
pandem
influenza
perform
antigen
test
detect
new
strain
known
inde
pandem
influenza
lower
season
influenza
center
diseas
control
prevent
ginocchio
et
al
landri
ferguson
case
clinic
diagnosi
test
modal
essenti
mani
assay
format
use
detect
antibodi
also
use
detect
viral
antigen
autom
spia
wide
use
detect
hbv
antigen
hbsag
hbeag
fourth
gener
autom
clia
hiv
antibodi
assay
also
includ
detect
hiv
antigen
rotaviru
shed
high
titer
stool
infant
commonli
detect
manual
microtiterpl
enzymelink
immunosorb
assay
elisa
dennehi
et
al
autom
immunoassay
dennehi
et
al
direct
immunofluoresc
assay
dfa
detect
viral
antigen
infect
cell
wide
use
diagnosi
respiratori
viru
infect
herpet
skin
lesion
detect
cmv
matrix
protein
nuclei
peripher
blood
leukocyt
pbl
cmv
antigenemia
first
cmv
viral
load
test
blood
retain
advantag
molecular
method
van
der
bij
et
al
gerna
et
al
landri
ferguson
dfa
perform
mani
cellular
sampl
type
especi
nasopharyng
wash
aspir
swab
bronchoalveloar
lavag
skin
mucos
lesion
pbl
tissu
biopsi
cell
collect
patient
pellet
centrifug
appli
glass
slide
fix
stain
antibodi
coupl
fluorophor
examin
fluoresc
microscop
virusspecif
stain
fig
b
color
intens
stain
distribut
viral
protein
within
infect
cell
infect
specif
cell
type
number
posit
cell
impact
interpret
landri
cmv
antigenemia
pbl
appli
per
slide
number
posit
cell
count
reagent
compris
pool
mab
differ
virus
caus
similar
clinic
syndrom
thu
singl
reagent
screen
multipl
virus
singl
cell
spot
exampl
includ
respiratori
viru
screen
reagent
seven
eight
respiratori
virus
rsv
influenza
b
parainfluenza
type
adenoviru
hmpv
landri
ferguson
screen
reagent
posit
addit
slide
stain
identifi
specif
pathogen
use
either
singl
fluoresceinlabel
antibodi
dualantibodi
reagent
two
differ
fluorophor
label
dual
fluorophorelabel
antibodi
pool
also
use
detect
differenti
hsv
vzv
brumback
et
al
advantag
dfa
antigen
detect
method
includ
greater
sensit
abil
assess
sampl
adequaci
ie
suffici
number
target
cell
abil
detect
multipl
virus
singl
test
chan
et
al
limit
includ
need
suffici
target
cell
fluoresc
microscop
dark
room
meticul
techniqu
slide
prepar
expertis
interpret
distinguish
specif
nonspecif
stain
landri
ferguson
assay
time
hour
longer
simpler
rapid
test
landri
nevertheless
dfa
shown
improv
patient
care
provid
cost
save
reduc
use
antibiot
barenfang
et
al
ic
assay
avail
rotaviru
dennehi
et
al
wide
use
detect
influenza
b
rsv
approv
pointofcar
test
sampl
ad
sampl
pad
port
viral
antigen
present
bound
label
antivir
antibodi
antigenantibodi
complex
move
along
strip
capillari
action
captur
test
area
virusspecif
antibodi
lead
appear
visibl
band
fig
excess
label
antibodi
continu
migrat
strip
captur
control
area
antiigg
ic
assay
larg
replac
membran
eia
rapid
test
format
sinc
ic
simpli
requir
addit
sampl
follow
set
timer
minut
depend
test
contrast
eia
reagent
addit
wash
step
newton
et
al
landri
et
al
ic
test
requir
equip
perform
nonlaboratori
personnel
limit
ic
includ
low
sensit
compar
detect
method
center
diseas
control
prevent
ginocchio
et
al
uyeki
et
al
abil
detect
one
two
differ
virus
influenza
b
rsv
improp
collect
devic
transport
condit
sampl
applic
techniqu
failur
read
result
promptli
contribut
falseposit
neg
ic
result
newer
method
util
small
instrument
enhanc
sensit
avoid
error
interpret
result
transcript
latex
bead
coat
virusspecif
antibodi
use
detect
viral
antigen
rotaviru
enter
adenoviru
stool
infant
recent
noroviru
de
es
et
al
lee
et
al
mix
stool
extract
antibodyco
bead
clump
viral
antigen
present
earli
molecular
method
esoter
expens
sensit
antigen
cultur
method
thu
wide
appli
clinic
arena
first
clinic
viral
molecular
test
use
nonamplifi
nucleic
acid
hybrid
radioisotopelabel
probe
detect
human
papillomaviru
hpv
dna
cervic
sampl
test
hpv
avail
ish
use
nonradioact
probe
tissu
sampl
ebv
next
advanc
hybrid
captur
wherebi
nucleic
acid
hybrid
solut
captur
mab
detect
subsequ
introduc
hbv
dna
quantif
contrast
earli
nonamplifi
assay
pcr
amplifi
target
nucleic
acid
millionfold
greatli
increas
sensit
revolution
viral
diagnost
especi
diagnosi
cn
infect
number
nucleic
acid
amplif
test
naat
strategi
avail
pcr
remain
wide
use
quantit
viral
nucleic
acid
determin
viral
load
possibl
essenti
manag
viral
infect
hiv
cmv
hbv
hcv
complex
natur
molecular
test
lack
fdaapprov
kit
mani
virus
limit
test
larg
academ
center
refer
laboratori
recent
innov
expand
avail
molecular
test
tabl
convent
pcr
consist
three
step
extract
purif
nucleic
acid
amplif
target
sequenc
use
specif
primer
dna
polymeras
detect
amplifi
fragment
amplicon
molecular
assay
reli
upon
complementari
basepair
inher
nucleic
acid
effect
amplif
templat
amplif
either
dna
rna
saiki
et
al
saiki
et
al
mulli
faloona
amplifi
test
perform
viral
nucleic
acid
must
isol
inhibitori
substanc
remov
nucleic
acid
extract
method
rang
manual
fulli
autom
process
individu
sampl
handl
highthroughput
process
multipl
sampl
time
method
vari
abil
extract
rna
dna
total
nucleic
acid
may
perform
differ
differ
sampl
type
vari
degre
concentr
nucleic
acid
final
extract
rel
input
sampl
thu
extract
method
use
greatli
impact
sensit
final
result
tradit
nucleic
acid
isol
techniqu
use
phenolchloroform
supplant
method
singlesampl
spin
column
kit
isol
either
dna
rna
bind
resin
follow
alkalin
lysi
cell
wash
nucleic
acid
elut
aqueou
solut
bind
nucleic
acid
silica
bead
solut
follow
wash
centrifug
remov
impur
elut
buffer
anoth
common
strategi
kit
requir
signific
handson
time
amen
highthroughput
test
number
autom
extract
devic
avail
use
magnet
silica
nucleic
acid
isol
use
conjunct
mani
differ
naat
instrument
extract
kit
specif
specimen
type
includ
sputum
tissu
bodi
fluid
swab
platform
use
singl
protocol
sampl
type
extract
dna
rna
total
nucleic
acid
yang
et
al
amplif
pcr
use
small
dna
primer
approxim
basepair
bp
bind
complementari
region
target
nucleic
acid
sequenc
temperatur
dna
primer
anneal
target
dna
sequenc
depend
length
primer
sequenc
target
case
around
c
pcr
use
thermost
dna
polymeras
origin
isol
thermu
aquaticu
taq
bacterium
live
hot
spring
whose
optim
activ
around
c
howev
taq
polymeras
rel
stabl
higher
temperatur
approxim
c
requir
melt
larger
strand
doublestrand
dna
dsdna
gener
pcr
singl
strand
thermost
taq
polymeras
allow
multipl
amplif
cycl
consist
rais
temperatur
c
melt
dsdna
lower
temperatur
c
allow
primer
anneal
rais
temperatur
c
polymeras
activ
repeat
cycl
target
dna
doubl
cycl
exponenti
expans
origin
nucleic
acid
sequenc
occur
facilit
detect
sinc
dna
templat
pcr
amplif
revers
transcriptas
rt
must
use
synthes
complementari
dna
cdna
segment
rna
templat
rna
virus
prior
pcr
pcr
perform
cdna
gener
rt
refer
rtpcr
confus
realtim
pcr
see
pcr
assay
viru
vari
tremend
gene
target
primer
sequenc
select
reaction
compon
amplif
condit
assay
intend
broadli
reactiv
other
select
certain
viru
genotyp
serotyp
origin
describ
convent
endpoint
pcr
amplifi
product
detect
agaros
gel
electrophoresi
amplif
complet
small
volum
pcr
reaction
load
agaros
gel
impregn
ethidium
bromid
highli
carcinogen
fluoresc
molecul
tightli
bind
dna
product
separ
base
length
dsdna
fragment
amplifi
pcr
product
visual
distinct
band
appropri
size
illumin
ultraviolet
light
altern
amplicon
transfer
southern
blot
spot
directli
nitrocellulos
hybrid
specif
probe
convent
pcr
requir
rel
inexpens
thermocycl
gel
visual
system
howev
vial
must
open
order
remov
aliquot
detect
aerosol
dna
amplicon
lead
contamin
instrument
surfac
glove
cloth
present
high
risk
contamin
subsequ
pcr
reaction
unidirect
work
flow
protocol
use
three
separ
room
extract
amplif
detect
wide
use
molecular
laboratori
anoth
common
strategi
substitut
uracil
dutp
thymidin
dttp
reaction
master
mix
gener
dna
amplicon
contain
uracil
instead
thymidin
subsequ
addit
uracilnglycosylas
ung
reaction
prior
pcr
prevent
uracilcontain
amplicon
nativ
dna
serv
templat
amplif
pang
et
al
quantit
convent
pcr
requir
pcr
multipl
dilut
start
materi
serial
dilut
amplicon
follow
plate
hybrid
quantit
viral
load
test
hiv
hbv
hcv
origin
perform
manner
supplant
altern
techniqu
case
realtim
pcr
method
major
impact
diagnost
test
realtim
pcr
combin
amplif
detect
one
step
shorten
assay
time
reduc
amplicon
crosscontamin
reaction
tube
open
allow
visual
amplif
result
unfold
real
time
realtim
pcr
method
commonli
use
fluoresc
dr
peaper
ml
landri
dnabind
dye
sybr
green
analog
ethidium
bromid
gel
electrophoresi
hybrid
fluoresc
dna
probe
livak
et
al
wittwer
et
al
thu
realtim
assay
requir
use
thermocycl
builtin
light
sourc
filter
detector
sybr
green
similar
dye
becom
fluoresc
upon
dna
bind
higher
affin
dsdna
molecul
amount
dsdna
creat
pcr
increas
fluoresc
signal
aris
dye
also
increas
assay
requir
complementari
dna
probe
detect
could
benefici
detect
virus
sequenc
variabl
howev
dye
bind
dsdna
includ
primer
dimer
nonspecif
amplifi
materi
also
render
sybr
dye
less
amen
multiplex
assay
develop
see
specif
determin
determin
melt
temperatur
dna
amplicon
uniqu
nucleic
acid
sequenc
espi
et
al
common
realtim
method
use
dna
probe
reli
upon
exonucleas
activ
taq
polymeras
commonli
refer
taqman
assay
taqman
assay
use
dna
probe
complementari
region
dna
amplifi
pcr
product
label
end
fluorophor
differ
excit
emiss
spectra
report
quencher
probe
intact
fluoresc
quench
refer
fluoresc
reson
energi
transfer
fret
target
sequenc
present
primer
probe
anneal
primer
extend
degrad
taqman
probe
also
call
hydrolysi
probe
lead
separ
report
fluorophor
quencher
fig
ensu
cycl
amplif
fluoresc
accumul
cross
threshold
posit
specif
cycl
amplif
also
known
cycl
threshold
ct
valu
fig
ct
valu
provid
indic
amount
viral
target
origin
sampl
lower
ct
valu
higher
viral
load
standard
known
viral
concentr
run
parallel
patient
sampl
absolut
valu
viral
load
calcul
use
standard
curv
fig
fret
hybridz
probe
also
refer
lightcycl
probe
molecular
beacon
two
common
probe
detect
format
use
realtim
pcr
espi
et
al
qualit
assay
result
report
simpli
posit
neg
ct
valu
provid
import
addit
inform
clinic
manag
follow
respons
treatment
serial
sampl
test
determin
two
virus
detect
predomin
pathogen
commun
laboratori
encourag
proper
interpret
result
sybr
green
taqman
assay
perform
varieti
realtim
pcr
instrument
may
vari
speed
cycl
reaction
vessel
use
number
sampl
test
singl
run
lightcycl
instrument
util
glass
capillari
reaction
vessel
reduc
time
requir
rais
lower
temperatur
amplif
cycl
thu
shorten
assay
time
smartcycl
also
uniqu
reaction
vessel
allow
faster
cycl
addit
reaction
unit
work
independ
thermocycl
sampl
need
batchtest
appli
biosystem
instrument
abi
use
plate
higher
throughput
rapidcycl
option
abi
fast
dx
util
smaller
reaction
volum
avail
current
focu
test
develop
greater
autom
highvolum
lowvolum
test
laboratori
multiplex
test
detect
presenc
multipl
virus
singl
reaction
greatli
increas
effici
test
multiplex
assay
less
sensit
singl
test
realtim
pcr
instrument
incorpor
multipl
light
sourc
filter
allow
simultan
monitor
three
five
differ
fluorophor
allow
develop
multiplex
realtim
assay
commerci
avail
sever
kit
detect
influenza
b
rsv
well
intern
control
singl
test
legoff
et
al
liao
et
al
multiplex
four
target
convent
pcr
use
number
viral
target
limit
resolut
detect
method
earli
commerci
test
six
herpesvirus
csf
argen
use
convent
pcr
vzv
ebv
cmv
human
follow
plate
hybrid
avail
unit
state
research
use
ruo
test
calvario
et
al
fdaapprov
xtag
respiratori
viru
panel
prototyp
highli
multiplex
assay
use
convent
pcr
virusspecif
oligonucleotid
tag
bind
fluoresc
microspher
color
microspher
correspond
individu
viru
label
dna
strand
indic
whether
amplifi
product
present
detect
use
luminex
instrument
microfluid
laser
system
analog
use
flow
cytometri
monitor
individu
microspher
presenc
amplifi
nucleic
acid
system
multiplex
detect
respiratori
viru
target
one
reaction
mahoni
et
al
pabbaraju
et
al
highli
multiplex
assay
idaho
technolog
biofir
genmark
recent
fdaapprov
detect
respiratori
pathogen
unit
state
three
highli
multiplex
test
platform
differ
dramat
extract
amplif
andor
detect
biofir
filmarray
system
use
selfcontain
pouch
combin
extract
two
sequenti
pcr
reaction
nest
pcr
detect
singl
unit
result
take
approxim
hour
throughput
limit
one
sampl
per
instrument
per
hour
like
luminex
xtag
system
genmark
respiratori
viru
panel
requir
separ
extract
endpoint
pcr
amplif
system
use
proprietari
esensor
electrochem
detect
method
compar
studi
limit
genmark
assay
demonstr
sensit
compar
optim
individu
pcr
assay
filmarray
somewhat
less
sensit
loeffelholz
et
al
babadi
et
al
pierc
hodinka
filmarray
system
abl
perform
staff
wide
array
skill
level
gener
final
report
approxim
hour
contrast
hour
luminex
genmark
assay
xu
et
al
nanospher
develop
bead
microarray
technolog
capabl
highord
multiplex
avail
respiratori
viru
panel
limit
seven
analyt
albi
et
al
highli
multiplex
commerci
test
respiratori
virus
use
varieti
strategi
detect
differenti
amplifi
product
microarray
autom
analyz
autom
endpoint
melt
curv
capillari
electrophoresi
novel
strategi
nolt
et
al
raymond
et
al
highli
multiplex
method
almost
exclus
develop
detect
respiratori
pathogen
underli
technolog
appli
bodi
site
specimen
clinic
syndrom
could
caus
varieti
difficulttoidentifi
andor
distinguish
pathogen
gastrointestin
infect
sever
commerci
platform
use
nonpcr
molecular
techniqu
viral
diagnosi
tabl
nucleic
acid
sequencebas
amplif
nasba
transcriptionmedi
amplif
tma
highli
relat
demonstr
compar
perform
pcr
assay
guatelli
et
al
giachetti
et
al
nasba
tma
amplifi
rna
target
sequenc
commerci
applic
use
differ
techniqu
detect
amplifi
materi
molecular
beacon
hybrid
protect
assay
hpa
respect
giachetti
et
al
landri
et
al
like
taqman
probe
molecular
beacon
dr
peaper
ml
landri
oligonucleotid
probe
report
quencher
fluorophor
end
molecular
beacon
area
complementari
dna
within
probe
lead
hairpin
format
place
fluorophor
close
proxim
lead
fret
signal
upon
dna
bind
molecular
probe
unfold
fret
elimin
lead
increas
signal
nasba
molecular
beacon
realtim
techniqu
leon
et
al
hpa
use
nucleic
acidbind
acridinium
ester
unbound
form
inactiv
chemic
treatment
materi
amplifi
tma
acridinium
ester
hybrid
doublestrand
nucleic
acid
protect
inactiv
addit
activ
compound
lead
product
visibl
light
protect
nucleic
acidassoci
acridinium
ester
read
instrument
hpa
endpoint
detect
techniqu
rather
realtim
branch
dna
bdna
assay
amplifi
nucleic
acid
present
origin
sampl
molecul
serv
templat
upon
multipl
layer
complementari
probe
built
dewar
et
al
mellor
et
al
final
layer
oligonucleotid
coupl
enzym
presenc
appropri
substrat
gener
fluoresc
signal
bdna
suscept
amplicon
carryov
less
technic
demand
simpler
implement
current
pcr
assay
techniqu
lend
develop
homebrew
see
assay
without
substanti
support
addit
molecular
methodolog
describ
use
area
clinic
diagnost
howev
none
develop
viral
diagnosi
increasingli
manufactur
develop
simpler
walkaway
test
platform
broaden
avail
molecular
test
laboratori
perform
lowercomplex
test
system
entir
selfcontain
close
develop
laboratori
develop
assay
other
open
outsid
assay
requir
greater
degre
technic
oversight
theoret
possibl
exist
assay
could
adapt
run
platform
like
manufacturerproduc
assay
primari
focu
develop
genexpert
system
cepheid
origin
implement
anthrax
screen
post
offic
use
cartridg
sampl
ad
contain
reagent
fluidic
need
nucleic
acid
extract
realtim
pcr
first
system
fulli
autom
integr
step
sampl
prepar
final
report
randomaccess
result
avail
hour
assay
enteroviru
csf
fdaapprov
system
kost
et
al
sefer
et
al
initi
instrument
could
test
one
four
sampl
walkaway
format
new
instrument
test
depend
instrument
configur
genexpert
filmarray
system
use
complex
fluidic
incorpor
nucleic
acid
extract
simpletous
cartridg
pouch
respect
focu
diagnost
develop
direct
sampletoansw
assay
influenza
influenza
b
rsv
reli
upon
proprietari
pcr
reaction
mix
minim
inhibitori
effect
patient
specimen
allow
detect
approxim
hour
albi
et
al
larg
number
analytespecif
reagent
asr
see
also
avail
platform
includ
assay
detect
vzv
cmv
run
without
extract
fulli
autom
system
use
novel
strategi
develop
fdaclear
avail
manufactur
viral
diagnost
assay
base
microarray
mass
spectrometr
analysi
amplifi
nucleic
acid
nextgener
sequenc
horizon
wang
et
al
ecker
et
al
remain
determin
whether
techniqu
costeffect
offer
enough
clinic
benefit
term
diagnost
util
improv
laboratori
work
flow
patient
manag
becom
wide
adopt
microarray
mass
spectrometr
assay
may
allow
multiplex
detect
greater
varieti
virus
without
loss
sensit
method
complex
requir
substanti
commerci
develop
sequenc
current
use
viral
genotyp
assess
antivir
resist
nextgener
sequenc
techniqu
quantit
abl
detect
small
subpopul
resist
virus
may
clinic
relev
simen
et
al
determin
resist
suscept
antivir
drug
phenotyp
genotyp
assay
use
phenotyp
assay
requir
growth
viru
presenc
increas
concentr
drug
determin
drug
concentr
reduc
infect
hsv
grow
readili
cultur
phenotyp
test
result
obtain
within
sever
week
slow
growth
cmv
delay
phenotyp
resist
result
month
larg
replac
genotyp
test
chou
et
al
teba
et
al
safrin
et
al
current
hiv
phenotyp
test
util
recombin
viru
assay
rt
proteas
gene
laboratori
diagnosi
viral
infect
amplifi
patient
plasma
ligat
viral
vector
transfect
suitabl
cell
line
chang
viral
replic
presenc
drug
monitor
phenotyp
test
essenti
identifi
new
mutat
associ
drug
resist
hiv
avail
special
refer
laboratori
phenotyp
result
often
express
fold
resist
compar
wildtyp
viru
petropoulo
et
al
drug
resist
genotyp
involv
pcr
amplif
gene
target
antivir
agent
follow
sequenc
identifi
known
drug
resist
mutat
commonli
undertaken
hiv
cmv
test
hbv
influenza
becom
import
well
olivero
et
al
deyd
et
al
genotyp
assay
determin
known
resist
mutat
present
signific
identifi
novel
mutat
imposs
interpret
bennett
et
al
hcv
genotyp
mere
identifi
patient
viru
genotyp
order
predict
treatment
respons
determin
length
therapi
identifi
drug
resist
mutat
common
hcv
genotyp
assay
noncod
core
region
viral
genom
amplifi
allow
bind
immobil
oligonucleotid
probe
test
strip
line
probe
assay
pattern
dna
bind
correl
particular
viru
genotyp
individu
gene
sequenc
verbeeck
et
al
quantit
viral
nucleic
acid
molecular
assay
import
manag
sever
acut
chronic
infect
quantit
assay
frequent
perform
hiv
hcv
cmv
ebv
bk
viru
adenoviru
import
hiv
hcv
viral
load
manag
affect
patient
world
health
organ
develop
intern
standard
commerci
avail
assay
calibr
saldanha
et
al
glaubitz
et
al
thu
viral
load
obtain
use
one
assay
viral
load
obtain
use
differ
platform
laboratori
world
howev
standard
exist
virus
widespread
use
homebrew
assay
make
comparison
laboratori
nearli
imposs
recent
intern
studi
cmv
ebv
viral
load
test
transplant
center
found
differ
quantit
copiesml
laboratori
test
sampl
preiksaiti
et
al
aspect
assay
procedur
eg
sampl
type
extract
method
molecular
target
primer
probe
sequenc
master
mix
amplif
protocol
contribut
quantit
viral
nucleic
acid
modif
paramet
could
give
differ
result
intern
standard
cmv
recent
becom
avail
assay
manufactur
independ
laboratori
freyer
et
al
effort
way
develop
intern
standard
virus
time
quantit
result
obtain
singl
laboratori
madej
et
al
multipl
laboratori
must
use
care
correl
viral
load
test
laboratori
perform
regul
test
approv
process
differ
part
world
affect
test
avail
unit
state
fda
approv
test
kit
vitro
diagnost
ivd
use
kit
must
undergo
rigor
test
compani
develop
kit
qualiti
control
perform
manufactur
implement
ivd
test
requir
limit
intern
valid
studi
diagnost
laboratori
contrast
ivd
test
assay
may
commerci
avail
asr
ruo
kit
contain
reagent
requir
perform
assay
undergon
test
requir
fda
approv
instead
onu
expens
clinic
valid
studi
incur
diagnost
laboratori
final
test
categori
homebrew
laboratorydevelop
test
homebrew
test
frequent
base
upon
assay
publish
literatur
perform
laboratori
respons
obtain
necessari
reagent
must
perform
qualiti
control
reagent
addit
homebrew
test
must
undergo
extens
intern
valid
process
mani
laboratori
staf
expertis
perform
step
requir
implement
homebrew
test
assay
use
asr
ruo
kit
may
also
problemat
given
valid
requir
howev
despit
increas
number
commerci
assay
avail
detect
respiratori
virus
number
virus
ivd
molecular
diagnost
kit
avail
small
thu
laboratori
may
reli
upon
less
rapid
test
send
sampl
refer
laboratori
comprehens
test
intern
differ
regulatori
environ
appli
sampl
collect
determin
clinic
syndrom
virus
differenti
knowledg
pathogenesi
test
order
requir
test
laboratori
tabl
laboratori
provid
collect
guidelin
appropri
test
dr
peaper
ml
landri
offer
includ
sampl
type
volum
proper
contain
transport
media
stabil
need
transport
temperatur
special
instruct
optim
result
sampl
collect
instruct
strictli
follow
gener
principl
provid
nasopharyng
swab
insert
deep
nasopharynx
past
point
resist
rotat
collect
ciliat
cell
lesion
unroof
steril
needl
scalpel
cell
base
lesion
collect
vesicl
fluid
contain
high
titer
viru
also
absorb
swab
virus
shed
stool
stool
sampl
contain
viru
prefer
rectal
swab
sampl
submit
cultur
requir
care
handl
order
preserv
viral
infect
swab
tissu
biopsi
place
viral
transport
media
antimicrobi
prevent
dri
reduc
overgrowth
bacteri
fungal
pathogen
bodi
fluid
aspir
wash
stool
sampl
place
steril
contain
transport
specimen
c
prefer
freez
sampl
c
lead
loss
viral
infect
avoid
freez
c
subsequ
thaw
reduc
infect
mani
envelop
virus
recommend
transport
laboratori
delay
sever
day
rapid
viral
antigen
detect
kit
use
rapid
influenza
test
manufactur
guidelin
sampl
type
collect
devic
transport
follow
especi
nonamplifi
test
rapid
flu
test
sampl
dilut
transport
media
minim
dilut
reduc
alreadi
limit
test
sensit
molecular
test
viral
nucleic
acid
particularli
dna
stabl
viral
infect
howev
quantit
molecular
method
perform
blood
requir
separ
serum
plasma
cell
within
hour
accur
result
likewis
blood
submit
quantit
cmv
antigenemia
process
cell
fix
within
hour
collect
accur
result
qualit
pcr
test
viral
load
low
occur
csf
sampl
improp
storag
delay
process
give
fals
neg
result
serum
sampl
antibodi
studi
transport
room
temperatur
c
prefer
contrast
sampl
cultur
pcr
freez
serum
c
accept
antibodi
studi
pair
sampl
includ
earliest
avail
sampl
onset
ill
later
day
onset
second
sampl
collect
day
week
later
document
seroconvers
igg
sampl
igm
collect
first
week
ill
neg
second
sampl
collect
second
week
suspicion
remain
high
rapid
hiv
test
perform
point
care
whole
blood
fingerstick
oral
mucos
transud
test
sampl
sent
laboratori
blood
collect
anticoagul
lavend
top
tube
provid
rapid
result
serum
submit
red
top
tube
instead
plasma
delay
minut
requir
blood
clot
centrifug
test
perform
although
test
csf
often
consid
direct
mean
diagnosi
cn
diseas
highli
neuropath
virus
may
present
insuffici
titer
csf
despit
cn
tissu
diseas
thu
test
sampl
essenti
exampl
includ
test
stool
enteroviru
type
polioviru
landri
et
al
furthermor
neurolog
syndrom
immunemedi
viru
may
present
csf
detect
peripher
site
syndrom
associ
mani
differ
virus
viral
diagnost
becom
integr
part
clinic
manag
result
avail
within
hour
day
rather
week
past
laboratori
must
select
extens
grow
armamentarium
test
test
offer
site
base
patient
popul
serv
need
rapid
result
facil
equip
expertis
avail
promin
role
convent
cultur
long
gold
standard
declin
rapid
cultur
limit
menu
provid
result
clinic
use
timefram
rapid
antigen
test
allow
test
influenza
rsv
hospit
clinic
without
virolog
laboratori
result
avail
within
minut
point
care
although
sensit
rapid
test
suboptim
especi
virus
antigen
variabl
young
children
shed
high
titer
viru
impact
reduc
unnecessari
antibiot
test
document
bonner
et
al
dfa
stain
clinic
sampl
enjoy
wider
applic
past
year
herpet
skin
lesion
respiratori
virus
cmv
viral
load
blood
due
highqual
commerci
mab
pool
antibodi
reagent
multiplex
screen
specimen
use
multipl
fluorophor
label
differenti
antibodi
dfa
valuabl
method
done
well
due
rel
speed
multiplex
capabl
greater
sensit
compar
rapid
antigen
test
inde
singl
posit
cell
detect
dfa
also
shown
improv
care
reduc
cost
barenfang
et
al
howev
dfa
requir
fluoresc
microscop
extens
experi
judgment
differenti
specif
nonspecif
stain
attent
detail
continu
monitor
compar
cultur
pcr
maintain
qualiti
also
manual
factor
limit
avail
dr
peaper
ml
landri
serolog
still
test
choic
acut
infect
arbovirus
lymphocyt
choriomening
viru
measl
rubella
diseas
symptom
immunemedi
diagnosi
antibodi
respons
play
central
role
exampl
includ
ebv
parvoviru
hav
hbv
serolog
test
transit
manual
laboratorydevelop
test
use
serial
dilut
serum
commerci
kit
test
singl
serum
aliquot
rather
whole
viru
grown
cell
cultur
antigen
sourc
current
test
commonli
use
synthet
peptid
recombin
protein
improv
test
specif
reproduc
instrument
allow
autom
random
access
demand
batch
test
interfac
directli
laboratori
comput
system
order
detect
earli
hiv
infect
igg
develop
current
spia
format
allow
detect
igm
well
igg
assay
includ
antigen
detect
class
captur
becom
prefer
test
igm
reduc
fals
posit
fals
neg
simpl
pointofcar
test
hiv
antibodi
allow
result
report
patient
still
clinic
nevertheless
import
rememb
initi
antibodi
test
may
neg
sampl
second
week
ill
west
nile
viru
igm
csf
may
need
establish
diagnosi
busch
et
al
addit
crossreact
among
virus
famili
lead
misdiagnos
exampl
past
infect
vaccin
flaviviru
lead
spuriou
elisa
antibodi
result
flavivirus
prnt
may
need
establish
etiolog
primari
infect
ebv
lead
falseposit
cmv
igm
vice
versa
thu
antibodi
eb
nuclear
antigen
confirm
primari
ebv
infect
cmv
viral
load
blood
assess
cmv
activ
may
need
accur
diagnosi
molecular
amplif
method
revolution
diagnost
virolog
especi
cn
diseas
first
appli
test
csf
hsv
enceph
pcr
quickli
replac
brain
biopsi
cultur
method
choic
rowley
et
al
csf
pcr
standard
test
mani
virus
csf
realtim
pcr
method
reduc
assay
time
carryov
contamin
made
quantit
easier
allow
rapid
introduct
assay
laboratori
capabl
implement
homebrew
assay
howev
still
fdaclear
test
kit
chang
demand
grow
compani
see
opportun
respiratori
viru
test
especi
influenza
motiv
manufactur
make
simplifi
test
avail
routin
laboratori
despit
mani
advantag
molecular
method
import
rememb
falseposit
falseneg
result
occur
due
high
sensit
pcr
suscept
carryov
contamin
amplifi
dna
crosscontamin
posit
clinic
sampl
addit
latent
virus
reactiv
without
symptom
mislead
clinician
ebv
carri
life
lymphocyt
presenc
csf
lymphocytosi
immunosuppress
ebv
dna
detect
csf
link
diseas
davi
et
al
blood
contamin
csf
give
rise
posit
csf
pcr
result
reflect
viremia
cn
infect
vzv
detect
csf
uncompl
zoster
cn
diseas
found
high
titer
blood
person
without
diseas
due
integr
viru
host
cell
chromosom
popul
unfortun
find
blood
unrel
ill
mislead
clinician
hubacek
et
al
inde
rise
titer
viru
blood
csf
often
greater
clinic
relev
posit
one
singl
point
time
molecular
test
untoward
effect
exampl
replac
enteroviru
cultur
csf
pcr
unanticip
consequ
elimin
detect
parechovirus
caus
similar
diseas
requir
separ
pcr
wide
avail
nix
et
al
unappreci
genet
variabl
viral
genom
mutat
lead
fals
neg
result
case
progress
multifoc
leukoencephalopathi
due
jc
viru
thu
impair
patient
manag
landri
et
al
lack
standard
major
issu
intern
quantit
standard
exist
benchmark
sensit
assay
one
multicent
studi
hsv
pcr
assay
result
sampl
contain
copi
hsvml
csf
fals
neg
schloss
et
al
two
intern
studi
transplant
center
cmv
ebv
viral
load
copi
number
report
sampl
vari
laboratori
preiksaiti
et
al
without
intern
standard
set
viral
load
cutoff
report
number
dna
copi
test
detect
meaningless
viral
diagnosi
extrem
dynam
rapidli
chang
field
tremend
progress
come
new
challeng
increas
complex
test
option
speed
methodolog
chang
discoveri
new
virus
therapi
imper
clinician
laboratori
profession
consult
latest
literatur
work
togeth
commun
optim
patient
test
result
interpret
